COVID-19和氯氮平在精神病服务早期干预中的应用

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2022-01-01 DOI:10.1002/pnp.737

Rizwana Jafry, Marlene Kelbrick

引用次数: 1

摘要

难治性精神分裂症的氯氮平处方未得到充分利用，包括精神病服务的早期干预。COVID - 19给氯氮平的使用带来了各种挑战，特别是在起始和监测方面。在这方面需要有明确的国家指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COVID‐19 and clozapine use in an early intervention for psychosis service

Clozapine prescribing in treatment‐refractory schizophrenia is underutilised, including in early intervention for psychosis services. COVID‐19 has brought various challenges to the utilisation of clozapine, particularly in the context of initiation and monitoring. There is a need for clear national guidance in this regard.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.